Skip to main content
. 2022 Dec 5;8(2):145–156. doi: 10.1016/S2468-1253(22)00389-2

Figure 4.

Figure 4

Cumulative hazard of time to breakthrough infection in patients with IBD treated with infliximab or vedolizumab after a third dose of SARS-CoV-2 vaccine

p value was calculated using a log-rank test.